Y
Yueyin Pan
Researcher at Anhui Medical University
Publications - 16
Citations - 871
Yueyin Pan is an academic researcher from Anhui Medical University. The author has contributed to research in topics: Breast cancer & Survival rate. The author has an hindex of 6, co-authored 16 publications receiving 237 citations.
Papers
More filters
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Caicun Zhou,Gongyan Chen,Yunchao Huang,Jianying Zhou,Lizhu Lin,Jifeng Feng,Zhe-Hai Wang,Yongqian Shu,Jianhua Shi,Yi Hu,Qiming Wang,Ying Cheng,Fengying Wu,Jianhua Chen,Xiaoyan Lin,Yongsheng Wang,Jian-An Huang,Jiuwei Cui,Lejie Cao,Yunpeng Liu,Yiping Zhang,Yueyin Pan,Jun Zhao,LiPing Wang,Jianhua Chang,Qun Chen,Xiubao Ren,Wei Zhang,Yun Fan,Zhiyong He,Jian Fang,Kangsheng Gu,Xiaorong Dong,Tao Zhang,Wei Shi,Jianjun Zou +35 more
TL;DR: The primary endpoint was met at the interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in all patients, supporting camrelIZumabplus carboplasin and pemberrexed as a first-line treatment option for Chinese patients with advanced non-squamous NSCLC.
Journal ArticleDOI
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zefei Jiang,Wei Li,X. C. Hu,Qingyuan Zhang,Tao Sun,Shude Cui,Shusen Wang,Quchang Ouyang,Yongmei Yin,Cuizhi Geng,Zhongsheng Tong,Ying Cheng,Yueyin Pan,Yuping Sun,Hong Wang,Tao Ouyang,Kangsheng Gu,Jifeng Feng,Xiaojia Wang,Shubin Wang,Tianshu Liu,Jinghua Gao,Massimo Cristofanilli,Zhiqiang Ning,Xianping Lu +24 more
TL;DR: Tucidinostat plus exemestane improved progression-free survival compared with placebo plus exEMestane in patients with advanced, hormone receptor-positive, HER2-negative breast cancer.
Journal ArticleDOI
LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Jianming Xu,H. Jiang,Yueyin Pan,K. Gu,S. Cang,L. Han,Y. Shu,Junhua Li,J. Zhao,Hongming Pan,S. Luo,Yanru Qin,Q. Guo,Yuxian Bai,Y. Ling,Y. Guo,Z. Li,Yinkun Liu,Yongyan Wang,H. Zhou +19 more
Journal ArticleDOI
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu,Qingyuan Zhang,Pin Zhang,Xichun Hu,Wei Li,Zhongsheng Tong,Tao Sun,Yuee Teng,Xinhong Wu,Quchang Ouyang,Xi Yan,Jing Cheng,Qiang Liu,Jifeng Feng,Xiaojia Wang,Yongmei Yin,Yanxia Shi,Yueyin Pan,Yongsheng Wang,Weimin Xie,Min Yan,Y Liu,Ping Yan,Fei Wu,Xiaoyu Zhu,Jianjun Zou +25 more
TL;DR: In this paper, a double-blind, randomized, phase 3 trial of dalpiciclib (a new cyclin-dependent kinase 4 and 6 inhibitor) plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer (ABC) with disease progression after endocrine therapy was presented.